You are here

P&T August 2012

Features

Health Care Reform
The Next Critical Step: Educating Consumers and Small Businesses

By the end of 2012, states must figure out how they will provide exchanges for citizens to buy health care insurance. Much work remains to be done, including removing information barriers, to make health care accessible to all citizens by 2014.

Challenges and Solutions for Physicians and Patients

Four recently approved drugs (cabazitaxel, sipuleucel-T, abiraterone, and denosumab), along with emerging therapies, bone-building therapies, hormonal treatments, and immunotherapies, have all demonstrated promise in advanced prostate cancer. It appears that the best outcomes will be achieved from the sequential use of multiple agents.

Clinical and Economic Outcomes

Men with benign prostatic hyperplasia who received 5-ARIs and persisted with therapy had significantly reduced risks of acute urinary retention, less need for prostate surgery, and lower medical costs.

Meeting Highlights
27th Annual Scientific Meeting and Exposition
Selected ASCO topics include drugs for melanoma, gastrointestinal tumors, non–small-cell lung cancer, and advanced breast cancer. ASH presentations cover ambulatory blood pressure in type-2 diabetes, triple therapy in obese patients, the effect of body mass on cardiovascular outcomes, and a novel glucagon-like peptide agonist for diabetes.

Departments

Medication Errors
Mixups of epidural and intravenous drugs can be deadly.
Prescription: Washington
The FDA’s PDUFA reauthorization bill passes but omits significant safety provisions.

FDA approvals, drug indications, and updates

Drug Forecast
Cabazitaxel (Jevtana) for metastatic castration-resistant prostate cancer